Hospital Ethics Approval: how it works and where it is recognized

Last reviewed 2026-05-16 by Reserve Meds clinical and regulatory team.

What Hospital Ethics Approval is

Origin and authorising body. Hospital ethics committees (IRBs, ethics committees) operate under each destination country's research-ethics regulations and hospital governance requirements. The authorising body for each individual case is the hospital ethics committee or institutional review board (IRB), with the relevant pharmacy or medicines regulator for the underlying authorisation, acting under that jurisdiction's pharmacy or medicines legislation.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

Legal basis. Hospital ethics review intersects with named-patient and compassionate-use frameworks at varying depth across jurisdictions. In some countries (notably France, Italy, Spain, and several Gulf jurisdictions), hospital ethics approval is a required step in the named-patient authorisation pathway. In others (UK Individual Patient Supply, German Einzelimport), ethics review is required only for research-grade cases or advanced therapy medicinal products and is not required for routine specialty-supply cases.

Hospital Ethics Approval is the institutional review layer that confirms a named-patient or compassionate-use authorisation meets ethical standards for the dispensing hospital. The committee reviews the clinical justification, the informed consent process, the monitoring plan, and (for cohort cases) the protocol. Approval is typically time-limited and may require renewal for ongoing cases.

Ethics review is most stringent for advanced therapy medicinal products, cohort programmes, and paediatric cases. For routine adult-supply named-patient cases in jurisdictions that do not require ethics review (UK, Germany, Nordic countries for routine cases), the framework adds review time and may slow the workflow. Where required (France, Italy, Spain, Gulf cohort programmes), ethics review is integrated into the regulator's authorisation timeline.

This page consolidates Reserve Meds's operational view of the Hospital Ethics Approval framework across the ten destination countries where we currently coordinate cross-border supply. Earlier in our content build we maintained separate per-country sub-pages for each Hospital Ethics Approval-in-country combination; those sub-pages remain available for archival reference but are no longer separately indexed, and the operational intelligence they carried has been folded into the country-compatibility table below.

Reserved for you.

Who can use Hospital Ethics Approval

Hospital Ethics Approval is sought by treating physicians at the dispensing hospital, typically through the hospital's pharmacy or clinical-research office. The committee reviews and authorises individual cases or protocols.

In practical terms, a Reserve Meds case opens when the treating physician has identified the clinical need, has reached a decision to prescribe a specific medicine, and has determined that the locally available route is unsuitable or unavailable. We then layer the regulatory and supply-chain coordination on top of that clinical decision; we do not originate the prescribing question and we do not advise on the clinical choice. The decision sits with the physician throughout.

Drug categories typically covered under Hospital Ethics Approval

All categories where the underlying pathway requires ethics review, particularly advanced therapy medicinal products, cohort programmes, paediatric cases, and complex compassionate-use scenarios.

The medicine itself must be source-country approved or in active regulatory development under a recognised reference authority (typically the US FDA, the European Medicines Agency, the UK MHRA, the Japan PMDA, or Health Canada). Most destination regulators will not authorise a Hospital Ethics Approval import for a medicine that lacks a recognised reference authorisation anywhere in the world, because the regulator's risk assessment leans on the source-country review as a substitute for its own.

Country compatibility

The table below summarises how the Hospital Ethics Approval framework is recognised across the ten destination countries where Reserve Meds currently coordinates cross-border supply. The "Accepts Hospital Ethics Approval dossiers" column reflects whether the destination regulator typically reviews and grants permits on the strength of a Hospital Ethics Approval clinical justification packet, or whether the patient must use a different parallel framework on the receiving side. Timelines reflect routine cases with a complete documentation set; first-import scenarios, paediatric weight-banded presentations, advanced therapy medicinal products, and large multi-cycle quantities can extend the regulator review by several weeks.

Notes. "Indirect" means the destination regulator does not directly accept Hospital Ethics Approval authorisation as the legal basis for import but does recognise a Hospital Ethics Approval authorisation as supporting precedent within its own named-patient or compassionate-use review. "Not applicable" means the framework is not a patient-access pathway in the cross-border sense and is shown here for completeness. Regulator names: NHRA (Bahrain), EDA (Egypt), CDSCO (India), JFDA (Jordan), KDFC (Kuwait), MoPH (Lebanon), MoH-DGPADC (Oman), MoPH-DPA (Qatar), SFDA (Saudi Arabia), and EDE (United Arab Emirates, federal from 29 December 2025).

Documentation required

A Hospital Ethics Approval application is typically assembled in coordination with the treating physician, the dispensing facility, and the cross-border supply partner. The documentation set below covers the routine case; specific destination countries may require additional items (most frequently a hospital ethics committee notification for paediatric or complex cases, and an insurer pre-authorisation letter where the patient intends to seek reimbursement).

• Clinical justification and treatment plan.
• Informed consent template.
• Hospital pharmacy infrastructure documentation.
• Manufacturer or supply chain documentation.
• For cohort cases: full protocol.
• Periodic outcome reporting where required.

Typical timeline

Hospital ethics review typically completes within 2 to 6 weeks. Where required, ethics review runs in parallel with regulator review. End-to-end: 4 to 8 weeks for routine cases, 8 to 16 weeks for advanced therapy cohort cases.

Costs and reimbursement

Ethics review fees vary by hospital and jurisdiction; typically nominal. Drug cost, logistics, customs, and coordinator fees run on the underlying pathway.

Where Reserve Meds fits in

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine access. For Hospital Ethics Approval cases, we coordinate the US-side sourcing through a DSCSA-compliant specialty channel, prepare the documentation packet your physician submits, coordinate validated cold-chain logistics with continuous temperature logging into the destination country, and assign a single named coordinator through the case. We do not replace your treating physician, we do not replace the destination-country regulator, and we do not replace your dispensing pharmacy. We coordinate the supply side so the physician can focus on patient care.

For each of the ten destination countries above, we publish a country-specific page documenting the operational realities (which dispensing facilities handle named-patient cases, how the cold chain is verified at the local airport, how the dispensing pharmacy releases the medicine, and what the typical insurer interaction looks like). Those country pages, combined with this pathway page and the specific drug pages, give the prescribing physician and the patient a coherent picture of what to expect before any commitment is made.

Our concierge fee is itemised separately on every firm quote alongside the drug acquisition cost, international logistics, customs, and dispensing pharmacy handling. The patient sees the full breakdown before deciding to proceed; we do not bundle costs and we do not charge an intake deposit. If the case cannot proceed for regulatory or supply reasons, we say so before any payment is taken.

Next step

If your treating physician has identified a clinical need that fits the Hospital Ethics Approval framework and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.

Start your caseWhatsApp

Reserved for you.

---

Related

• All access pathways
• UAE access landscape
• Saudi Arabia: SFDA named-patient pathway
• When conventional access fails
• How Reserve Meds works